disease
-
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Palliative & Hospice Care
Palliative Care Intervention for Patients with End Stage Liver Disease: A Cluster Randomized Controlled Trial
A groundbreaking study, published in JAMA, has investigated the efficacy of palliative care interventions for patients suffering from end-stage liver…
Read More » -
Nutrition & Diet for Elderly
Nutrition Science and the Food is Medicine Initiative: Transforming Chronic Disease Management through Dietary Intervention
The integration of nutrition into the primary healthcare framework represents one of the most significant shifts in modern medicine, moving…
Read More » -
Palliative & Hospice Care
Palliative Care Intervention for Patients with End-Stage Liver Disease: A Cluster Randomized Controlled Trial
A groundbreaking cluster randomized controlled trial published in JAMA has investigated the effectiveness of palliative care interventions for patients suffering…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting…
Read More » -
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
Alzheimer’s & Dementia Care
The Relentless Unraveling: Navigating the Complexities of Alzheimer’s Disease
Alzheimer’s disease is often described as a long farewell—a relentless unraveling of memory, identity, and connection, presenting a profound and…
Read More » -
Alzheimer’s & Dementia Care
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More » -
Palliative & Hospice Care
Alzheimer’s Disease, Amyloid, and Antibodies: Experts Grapple with Evolving Definitions and Treatment Dilemmas
The landscape of Alzheimer’s disease diagnosis and treatment is undergoing a profound transformation, driven by advancements in understanding the disease’s…
Read More » -
Alzheimer’s & Dementia Care
Blarcamesine Demonstrates Sustained Efficacy Over Three Years in Early Alzheimer’s Disease, Offering Hope for Disease Modification
Copenhagen, Denmark – In a significant development for Alzheimer’s disease research, Anavex Life Sciences has announced that the therapeutic benefits…
Read More »
